全球研发 | 复星医药芦沃美替尼研究成果入选 2025 ESMO 口头汇报,临床价值再添新证!

复星万邦
Oct 23, 2025

肿瘤领域盛会2025年欧洲肿瘤内科学会年会(ESMO 2025)将于当地时间10月17-21日在柏林召开。本次会议中,芦沃美替尼(FCN-159)治疗儿童低级别胶质瘤(pLGG)的II期研究成功入选口头报告。该项研究在此之前已成功入选2023 ESMO口头汇报1。基于更长随访数据,本项研究的数据更新结果再次获得ESMO大会口头汇报,这不仅是对本项研究的学术认可,更是复星医药在肿瘤领域深耕不辍、持续...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10